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1.1 Introduction
Human genome is the genetic blueprint of the
human being, which conveys all genetics
information necessary for a human. In general, the
term “human genome” refers to the DNAs on 22
pairs of autosomal chromosomes and 2 sex
chromosomes. DNAs contain 4 kinds of bases
(adenine, guanine, cytosine and thymine), and
human genome is composed of about 3 billion
base pairs. It has been said that, among all the
base pairs making up the human genome, only
about 3% corresponds to genes (regions encoding
genetic information).
The concept of the sequencing of the whole
human genome was already created in the mid
1980s. However, for reasons such as the fact that
an extremely long time was required to sequence
the whole human genome with the use of
techniques for sequencing at that time,
sequencing of the whole human genome was
thought to have only limited feasibility. However,
research on human genome has gradually become
active, and, in 1990, the International Human
Genome Sequencing Project was launched on a
full scale under the initiative of the United States.
While the project was originally planned to be
completed in 15 years, the date for the project’s
completion has been brought forward because of
the increase in performance of genome
sequencers as well as the entry of venture capital
companies into the project. As a result, in
February 2001, the Human Genome Sequencing
Consortium and Celera Genomics, a venture
capital company in the United States, separately
published that they have almost finished the
sequencing of the whole human genome.
The research conducted by utilizing the
determined base sequence of human genome is
called “post genome research.” Since post genome
research includes many factors that may lead
directly to future commercial applications,
cutthroat world-wide competition involving
private companies has been carried out in this
field.
This article summarizes the international trends in
human genome sequencing, trends in research
performed by Celera Genomics, a noteworthy
venture capital company in the United States, as
well as trends in post genome research in Japan.
1.2 International trends in
human genome sequencing
In February 2001, the International Human
Genome Sequencing Consortium and Celera
Genomics separately published articles on human
genome sequencing in the journals “Nature” and
“Science,” respectively (Chart 1).
1.2.1  Sequencing by the International Human
Genome Sequencing Consortium
Chart 2 shows the number of bases in finished
human sequences among the human genome
sequences entered into GenBank, a public base
sequence database.
With regard to the complete sequencing of a
specific pair of chromosome, a joint research team
composed of researchers from Japan, the United
Kingdom and the United States (Keio University,
Sanger Centre in the United Kingdom, as well as
the University of Oklahoma and Washington
University in the United States) finished the
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complete sequencing of chromosome 22. In
addition, Keio University, the Institute of Physical
and Chemical Research, etc., collaboratively
finished the complete sequencing of chromosome
21 in May 2000. The accuracy of the sequencing
of those chromosomes (chromosomes 21 and 22)
is as high as 99.99%, earning an excellent
reputation worldwide. Chromosome 22 has the
gene responsible for Parkinson's disease, genes
related to autoimmune diseases, etc., and
chromosome 21 has relations with Down's
syndrome (an extra chromosome 21 is detected in
Down's syndrome), a gene related to Alzheimer's
disease, etc. The sequencing of human genome
including such disease-related genes as those
mentioned above is expected to greatly expedite
the progress in research on the mechanism of
expression of those genes.
However, there still remain draft sequences, i.e.,
regions that are difficult to be completely
sequenced on chromosomes other than
chromosomes 21 and 22. The International
Human Genome Sequencing Consortium is still
pursuing the sequencing project, aiming to
complete the sequencing of the whole human
genome with high accuracy by the end of 2003.
1.2.2  Human Genome Sequencing by Celera
Genomics
Celera Genomics did not sequence each
chromosome separately but adopted the whole
genome shot-gun method where all the 24
chromosomes (22 pairs of autosomal
chromosomes and 2 sex chromosomes) were
Chart 1: Publishers of the human genome sequence
Journal Title Nature Science
February 15, 2001 issue February 16, 2001 issue
"Initial sequencing and analysis of the human "The Sequence of the Human Genome"
genome"
Publisher International Human Genome Sequencing Celera Genomics
Consortium (American venture capital company)
蘆 United States (Washington University; Joint
蘆 Genome Institute, Department of Energy; Baylor
蘆 College of Medicine; Whitehead Institute,
蘆 Massachusetts Institute of Technology, etc.)
蘆 United Kingdom (Sanger Centre, etc.)
蘆 France (Genoscope, etc.)
蘆 Japan (Institute of Physical and Chemical
蘆 Research [Riken], Keio University, etc.)
蘆 Germany, etc.
Chart 2: Finished human sequences entered into GenBank by institutions participating in the International Human
Genome Sequencing Consortium
Prepared by the Science and Technology Foresight Center based on Table 3 on page 868 in the February 15, 2001 issue of the journal
Nature.
Order of Research Organization Number of bases
entry sequenced  (kb)
1 The Sanger Centre (United Kingdom) 284,353
2 Washington University Genome Sequencing Center (United States) 175,279
3 US DOE Joint Genome Institute (United States) 78,486
4 Baylor College of Medicine Human Genome Sequencing Center (United States) 53,418
5 Genoscope (France) 48,808
6 Whitehead Institute, Center for Genome Research (United States) 46,560
7 Department of Genome Analysis, Institute of Molecular Biotechnology (Germany) 17,788
8 Institute of Physical and Chemical Research (Japan) 16,971
9 University of Washington Genome Center (United States) 14,692
10 Keio University (Japan) 13,058
Others 92,614
Total 842,027
(Total number of bases on the whole human genome.) about 3,200,000
simultaneously analyzed. At the first step of
Celera’s whole genome shot-gun protocol,
sampled human genome was randomly physically
sheared into small fragments of the same size (2
kb or 10 kb) by using ultrasound, and a library of
the fragments was constructed. At the next step,
the regions composed of about several hundred
base pairs at both ends of those fragments were
analyzed in DNA sequencers. Scientists then used
powerful computers to assemble the fragments
back into place to determine the sequence of the
whole human genome. According to Celera
Genomics, with the whole genome shot-gun
method, 95% of the whole human genome could
be sequenced with an accuracy of as high as
99.96%.
1.2.3  Access to the data on base sequences of
human genome
While the data on human genome sequences
entered into GenBank by the International Human
Genome Sequencing Consortium can be accessed
at no charge, you need to make a contract with
Celera Genomics in order to gain access to the
data on human genome sequences determined by
the company.
(1) Human genome sequences determined by
the International Human Genome
Sequencing Consortium
In the sequencing activities by the International
Human Genome Sequencing Consortium,
respective participating institutions are assigned
specific regions to be sequenced, and, if the
sequencing of a region is finished, the data on the
sequence of the region are to be immediately
entered into public databases including GenBank
and then made available for public view at no
charge. Those data entered on such public
databases include data on the base sequences of
the finished human sequences such as those of
chromosomes 21 and 22 as well as data on the
regions on draft sequences. As mentioned in
section 1.2.1, the sequencing of the whole human
genome must be completed by the International
Human Genome Sequencing Consortium before
free access and utilization of data on the sequence
of the whole genome with high accuracy become
possible.
(2) Human genome sequences determined by
Celera Genomics
Researchers, institutions, companies, etc., cannot
freely access or utilize the data on human genome
sequences obtained by Celera Genomics unless
they make a contract with the company. In
Australia, for example, a contract with Celera
Genomics has been made at a nation level, and
national institutions have access to the data on
human genome sequences determined by the
company. In Japan, some universities and private
companies individually contracted with Celera
Genomics to access the data on sequences
determined by the company.
1.3 Accomplishments in genome
sequence analysis achieved
by Celera Genomics and
strategies for pursuing post
genome research
In March 2001, Dr. J. Craig Venter, president of
Celera Genomics at the time, visited Japan, and he
commented as follows at his lecture, etc., about
genome sequence analysis and strategies for
pursuing post genome research:
(1)  Accomplishments in genome sequence
analysis
Celera Genomics, which was founded in 1998, has
determined the sequences of genomes of the
Drosophila (fruit fly), human beings, and mice (3
strains of mice including 129SvJ, DBA/2 and A/J).
Currently, the company is pursuing the sequence
analysis of canine and rat genomes. The company
has been able to accomplish a succession of
achievements in a short period of time against the
backdrop of; i) the introduction of 300 units of a
new automated sequencer (ABI3700), ii)
development of software for the whole genome
shotgun sequencing technique, and iii) the
introduction of the latest computers. In other
words, Celera Genomics has succeeded in
climbing on the bandwagon in terms of both
hardware and software.
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(2)  Current state of human genome
sequence analysis
The evolutionary process can be traced in human
genome. When viewing the sequences of the
human genome, many regions with similar
sequences can be seen on different chromosomes,
indicating that they have evolved from a common
ancestral chromosome.
In addition, while individual difference is noted in
the sequences of some regions on the human
genome, roughly 3 million single nucleotide
polymorphisms (SNPs) have been found which are
DNA sequence variations that occur when a single
nucleotide (A,T, C or G) in the genome sequence
is altered. Ultimately, 4 million SNPs will be found.
Among them, 1% or less exists on coding regions
of the human genome (genes), and only a fraction
of those SNPs cause amino acid substitution. On
the other hand, it is known that SNPs that occur in
non-coding regions could predispose people to
disease or influence their response to a drug, so
such SNPs (SNPs in the regions not encoding
proteins) are also of consequence.
(3) Strategies for pursuing post genome
research
At the facility for protein analysis (Proteomics
Factory), which has been established by Celera
Genomics, one million samples of proteins can be
structurally analyzed in a day with the use of mass
spectrometers. Celera Genomics thinks that about
250 thousand kinds of proteins are expressed
from roughly 30 thousand human genes by way of
genetic transcription, translation and post-
translational processing, and expects that causal
relationships can be found between abnormalities
of proteins and diseases. They have targeted
cancer and aim to develop cancer diagnostic
methods and cancer-specific vaccines.
According to the media, Celera Genomics has
made a capital investment in a Japanese venture
capital biotechnology company, which has SNPs
analysis technology and aims to reveal, for
example, the association between SNPs in
Japanese and diseases.
1.4 Trends in post genome
research in Japan
Post genome research on human genome may
have ripple effects on various fields in the form of,
for example, contributions to medical care,
facilitation of progress in advances in life science,
contributions to various industries, etc. shown in
Chart 3.
Such post genome research has come to be
accepted as important in the Phase Two
Technology Master Plan, which was adopted at the
Cabinet meeting held in March 2001. The plan
states that, among the areas of life science given
priority to in research and development in Japan,
post genome research should be given high
priority and pursued strategically among others.
Future directions of post genome research in
Japan are concretely charted in the report entitled
“Promotion of strategies for pursuing post genome
research” (report on a round-table conference
concerning the strategic promotion of post
genome research held by the Policy-making
committee of the Technology Council) published
in December 2000. The report states that the
areas of post genome research that must be
urgently pursued in Japan include the analysis of
human genome variability and genes related to
diseases, structural and functional analysis of
proteins, bioinformatics, as well as functional
analysis of genome. In addition, the report said
that Japan will be able to move ahead of other
countries in post genome research through urgent
pursuit of such research by utilizing technologies
in Japan that are superior to those in other
countries such as the techniques for creating full-
length cDNAs containing the complete genetic
information of the mRNA encoding amino acids,
which are used to form proteins (technique
developed by Dr. Sugano et al. at the Institute of
Medical Science, the University of Tokyo, and that
developed by Dr. Hayashizaki et al. at the Institute
of Physical and Chemical Research), and
techniques for inducing the expression of proteins
in the cell-free system (technique developed by
Dr.Yokoyama et al. at the Institute of Physical and
Chemical Research for efficiently inducing the
expression of, and preparing the sample of many
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kinds of proteins), as well as by utilizing “facilities”
in Japan that are better equipped than those in
other countries including the large-scale nuclear
magnetic resonance (NMR) park (Genomic
Science Center, Institute of Physical and Chemical
Research) and “SPring-8,” a third-generation
synchrotron radiation facility, at the Japan
Synchrotron Radiation Research Institute (JASRI).
In the budget plan for fiscal year 2001, 98.3 billion
yen was earmarked for the “strategies of
promoting research and development in the areas
of biotechnology with an eye toward life science
of the 21st century” by the Ministry of Education,
Culture, Sports, Science and Technology, the
Ministry of Agriculture, Forestry and Fisheries, and
the Ministry of Health, Labor and Welfare. Of the
98.3 billion yen, 60.6 billion yen (compared to
44.4 billion yen in fiscal year 2000) was allocated
to; i) analysis of human genome structure and
variability (structural and functional analysis of
human full-length cDNAs, research on SNPs, etc.)
and, ii) functional analysis of the human genome
(structural and functional analysis of proteins,
bioinformatics, etc.) to further facilitate such
research.
Concerning post genome research pursued in
Japan, this article describes trends in analysis of
conformational structures of proteins, studies on
SNPs found in Japanese as well as bioinformatics.
(1) Analysis of conformational structures of
proteins
No methods, which are based on the sequences of
the genome and are universally applicable, have
been found for predicting the functions of
proteins that are to be expressed from genes via
transcription and translation. However, projects
for analyzing conformational structures of
proteins, which may be closely associated with
their functions, are underway at institutions
including the Institute of Physical and Chemical
Research.
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Chart 3: Post genome research on human genome
Prepared by the Science and Technology Foresight Center
So far, conformational structures of 2,000 to 3,000
kinds of proteins have been elucidated, most of
which have been clarified in the United States.
The international research team composed of
researchers from Japan, the United States and
European countries is planning to elucidate the
conformational structures of 10,000 or more kinds
of proteins within the next 5-10 years. Japan is
aiming to complete the analysis of conformational
structures of about 3,000 kinds of proteins under
the initiative of the Institute of Physical and
Chemical Research within the next five years.
Moreover, the United States is targeting for the
completion of conformational analysis of roughly
5,000 kinds of proteins within the next 5 years.
While only a few percent of the whole sequences
determined by the International Human Genome
Sequencing Consortium was elucidated by
Japanese researchers, it can be expected that a
larger percentage will be represented by
conformational structures of proteins determined
in Japan among whole structures identified in the
world.
In the First International Structural Genomics
Meeting jointly held under the auspices of Japan,
the United States and the United Kingdom in April
2001, discussion was held by the representatives
of 10 countries on the conceptual framework of
international cooperation in protein analysis. In
the conference, it was agreed that situation reports
on research should be made through common
procedural steps based on the rule that every
piece of information obtained in such analysis
must be made public. Moreover, with regard to
the timing of the publication of data on the
conformational structures of proteins, it was
agreed that such data must be made public within
6 months at the maximum after obtaining the
relevant data, by giving consideration to the
possible unfairness that may be caused due to the
difference in patent application systems among
countries and in view of the fact that such data
may directly lead to future commercial
applications such as the development of
diagnostic methods and pharmaceutical products.
(2) Study on SNPs found in Japanese
Individual differences are seen in the sequences of
many regions of the human genome. Such
differences in base sequences are called genetic
polymorphisms which include; i) SNPs, ii)
insertion or deletion polymorphisms
(polymorphisms due to the insertion or deletion
in some regions of DNA), as well as iii) VNTR
(variable number of tandem repeat)
polymorphisms and microsatellite polymorphisms
(polymorphisms caused by the difference in the
number of repeat of a specific sequence made up
of two to several tens of bases; those due to the
differences of repeat number of sequences made
up of a few to several tens of bases and 2-4 bases
are called VNTR polymorphisms and microsatellite
polymorphisms, respectively).
While VNTR and microsatellite polymorphisms
can be found in several thousands and several tens
of thousand regions on the genome, respectively, it
has been said that SNPs are found in about as
much as 4 million regions (according to Dr. J. Craig
Venter, former president of Celera Genomics) or in
as much as 3-10 million regions (Prof. Yusuke
Nakamura, “Frontiers of Genetic Medicine,”
Yodosha Co., Ltd., 2000). In addition, since high-
speed and high throughput SNPs analyzers are
nearing practical use, SNPs may be more useful in
exploring disease-related genes. Therefore,
researchers assign a higher importance to SNPs as
compared with other polymorphisms.
Under these circumstances, analysis of some of the
SNPs found in Japanese was conducted at the
Institute of Medical Science, University of Tokyo,
and yielded results that suggest Japanese have
descended from a relatively genetically isolated
population, indicating the possibility that there
might be disease-related SNPs specific to Japanese.
The Institute of Medical Science, University of
Tokyo, has compiled data on SNPs into a computer
database and put it up for public view on the
Internet. In addition, the Pharma SNP Consortium
(organized by the Institute of Physical and
Chemical Research, Tokyo Women’s Medical
University, as well as 43 pharmaceutical
companies) is pursuing studies that may lead to
the promotion of tailored medicine including the
collection of DNA samples from a general
population (about 1,000 healthy volunteers) for
use in the analysis of polymorphisms of the 165
genes related to drug metabolizing enzymes.
It is expected that data on regions on the human
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genome in which individual differences are seen
in base sequences will be the key to future
individualized medical care, i.e., medical care
designed for each individual to offer maximum
therapeutic benefits in light of accurately
analyzing his/her genetic predisposition. On the
other hand, ethical problems have loomed about
how to handle individual genetic information. In
March 2001, the Ministry of Education, Culture,
Sports, Science and Technology, the Ministry of
Health, Labor and Welfare, and the Ministry of
Economy, Trade and Industry jointly drew up the
“Ethical Guidelines concerning the Analysis of
Human Genome and Genes,” which are the
concrete guidelines for ethical aspects of research
on human genome and genes in general. In the
guidelines, responsibilities to be assumed by
researchers and institutions included the pursuit
of genetic studies after gaining written informed
consent from the candidate suppliers of DNA
samples following detailed explanation of, for
example, the purposes of the relevant studies as
well as the guaranteed protection of privacy in
terms of genetic information. Moreover, 8 genetic
medicine-related societies in Japan including the
Japan Society of Human Genetics have jointly
drawn up draft guidelines as to the way human
genetic tests should be carried on.
(3) Bioinformatics
Rapid progress in human genome analysis has
created a need for processing enormous amounts
of data on base sequences. In order to accelerate
the progress in post genome research from now, it
may be essential to develop software that enables
us to not only manipulate data on base sequences
but also to predict the structures, functions,
metabolic pathways, etc., of proteins based on
amino acid sequences. Therefore, further
facilitation of studies in the field of bioinformatics,
in which databases of information that may form
the foundation of post genome research are
constructed to associate the extensive data to one
another, is thought to be an urgent necessity. In
particular, development of human resources, such
as specialists who are experts in both biology and
information science, has long been considered to
be a matter of high priority.
One example of specific efforts made by the
Japanese government is that bioinformatics was
selected as one of the fields (two fields in total
were selected) from among the research fields
proposed by the general public as those for which
monetary support for the development of human
resources must be provided from the Funds for
the Coordination of Advancement of Technology
for fiscal year 2001.
In addition, one example of a recent noteworthy
movement is that a seminar, “Information Biology
Teki-juku (training course for people with
Aptitude)” (Director: Dr. Kenichi Matsubara,
professor at Nara Institute of Science and
Technology), was held during the period from late
March to early April 2001 at the International
Institute for Advanced Studies, under the
sponsorship of the Ministry of Education, Culture,
Sports, Science and Technology, with the aim of
training professionals on information technology
necessary for studies in the field of life science
who can then be trailblazers and explore new
areas. These realities suggest that researchers also
recognize the significance of bioinformatics.
In the United States, biology is compulsory for all
students regardless of their specialties at some
universities, which would give a clue in devising
strategies for promoting the progress in
bioinformatics.
1.5 Conclusion
—Future prospects of the
movement surrounding human
genome sequences
(1) Human genome sequencing by the
International Human Genome Sequencing
Consortium is currently in progress
Currently, human genome sequencing is being
pursued by the Finishing Group (composed of
researchers from the United States, the United
Kingdom, Japan and France) of the International
Human Genome Sequencing Consortium, with the
aim to complete the sequencing of the whole
human genome with high accuracy. In the
Finishing Group, there are coordinating centers
that are responsible for the sequencing of specific
chromosomes as well as participating centers that
are to cooperate with sequencing chromosomes
where possible.
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In Japan, the Institute of Physical and Chemical
Research, a coordinating center, is pursuing the
sequencing of chromosomes 11 and 18 in
collaboration with the Whitehead Institute,
Massachusetts Institute of Technology. On the
other hand, Keio University, a participating center,
is engaged in the sequencing of chromosome 8.
(2) Applicability of genome research to
disease suppression
In order to apply the achievements in genome
research to disease suppression, it is necessary to
analyze such data on genome sequences as those
on SNPs in association with data on clinical
characteristics. The association method is one
example of such analytical methods with which
candidate disease-related genes will be identified
through comparing gene sequences of each
population of several hundred to several thousand
people affected by a specific disease with those of
each population of several hundred to several
thousand people free of the disease. For such
analysis, blood samples must be collected from a
relatively great many volunteers.
Japan lags behind some other countries in the
establishment of foundations on which to conduct
studies using such analytical method mentioned
above. It is difficult to collect blood samples from
a great many people at the level of each individual
institution and, therefore, some researchers obtain
such blood samples from abroad.
From here forward, in order to build up a solid
foundation on which to do post genome research
in Japan, it is urgently required to establish
resource centers where samples and clinical data
collected from many people, while following
specified procedures such as gaining informed
consent, are stored and managed at a national
level.
(3) Promotion of post genome research
In recent post genome research, the United States
has taken the international initiative, against the
backdrop of the aggressive establishment of
venture capital biotechnology companies, to
develop strategies for obtaining and protecting
U.S. patents. For example, about 1,500 venture
capital biotechnology companies were reported to
be established in the United States in 2000, in
contrast to about 150 companies in Japan
(Masamichi Ooishi,“Workings of Human Genome,”
Nippon Jitsugyo Publishing Co., Ltd., 2001).
Nevertheless, in Japan too, such various projects as
those mentioned under Section 1.4 of this article
have been prepared or launched under the
initiative of government. Private companies
including pharmaceutical companies are also
hurriedly promoting larger investments in
research targeting at genomic drug discovery, and
forming alliances for the sake of improving their
competitiveness in the field of bioinformatics as
well as promoting technical cooperation.
Furthermore, joint research projects between such
public institutions as the Institute of Physical and
Chemical Research and private companies have
been pursued, raising expectations that the
achievements in publicly funded studies will lead
to future commercial applications.
Post genome research will have an enormous
impact on Japan’s future life and economy, and
will be deeply involved in various aspects of
society, primarily concerning the ethical aspects.
Therefore, it may be required that research funds
and manpower be provided, while f lexibly
responding to changes in the social climate
surrounding post genome research as well as in
the environment for such research in Japan and
abroad, for its acceleration.
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C o m m e n t a r y
Percentage of base sequences determined by
Japanese among whole sequences analyzed by
the International Human Genome Sequencing Consortium
It has been frequently reported by the media, etc., that the rate of Japan’s contribution to
human genome sequencing pursued by the International Human Genome Sequencing
Consortium is about 6%. This value was calculated based on the percentage (5.59%) of the
total of sequences (3,934,884 kb) determined by the Institute of Physical and Chemical
Research (188,056 kb), Keio University (20,105 kb), and Tokai University together with two
societies for the study of cancer (11,783 kb in total) in the whole draft sequences determined
by the Consortium.
As of February 2001, when the article contributed by the International Human Genome
Sequencing Consortium appeared in the journal Nature, as much as 4,338,224 kb were
contained in the whole draft sequences, far exceeding (about 1.4 times) the estimated number
of bases making up the human genome. Such increase in bases in draft sequences is due in
part to the fact that institutions in countries other than Japan entered the data on the
sequences of the regions not assigned to them, which they determined in order to explore
SNPs entered into databases.
The values in Chart 2 are not the numbers of bases in the draft sequences, but those in finished
human sequences.
